

Please type a plus sign (+) inside this box

+

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0081
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/180,657
Filing Date	November 12, 1998
First Named Inventor	Peter J. Meikle
Group Art Unit	1644
Examiner Name	Nolan, Patrick J.
Attorney Docket Number	021385-014500US

Sheet 2 of 3

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PN	AB	BAGHDIGUIAN, S. et al.; Co-localization of suramin and serum albumin in lysosomes of suramin-treated human colon cancer cells; Cancer Letters; 1996; pp. 179-184; Vol. 101.	
	AC	BURKHARDT, JANIS K., et al.; The Giant Organelles in Beige and Chediak-Higashi Fibroblasts Are Derived from Late Endosomes and Mature Lysosomes; Journal of Experimental Medicine; December 1993; pp. 1845-1856; Volume 178.	
	AD	CHAMBERLAIN, PAUL, et al.; Generation and Characterization of Monoclonal Antibodies to Human Type-5 Tartrate-Resistant Acid Phosphatase: Development of a Specific Immunoassay of the Isoenzyme in Serum; Clinical Chemistry; 1995; pp. 1495-1499; Volume 41, No. 10.	
	AE	CONARY, JON T., et al.; Synthesis and Stability of Steroid Sulfatase in Fibroblasts from Multiple Sulfatase Deficiency; Biological Chemistry Hoppe-Seyler; April 1988; pp. 297-302; Volume 369.	
	AF	DAHLGREN, CLAES, et al.; The lysosomal membrane glycoproteins Lamp-1 and Lamp-2 are present in mobilizable organelles, but are absent from the azurophilic granules of human neutrophils; Biochemical Journal; 1995; pp. 667-674; Volume 311.	
	AG	KARAGEORGOS, LITSA E. et al.; Lysosomal Biogenesis in Lysosomal Storage Disorders; Experimental Cell Research; 1997; pp. 85-97; Volume 234.	
	AH	KISHIMOTO, YASUO et al; Saposins: structure, function, distribution, and molecular genetics; Journal of Lipid Research; 1992; pp. 1255-1267; Volume 33.	
	AI	MEIKLE, PETER J., et al.; Diagnosis of lysosomal storage disorders: evaluation of lysosome-associated membrane protein LAMP-1 as diagnostic marker; Clinical Chemistry; 1997; pp. 1325-1335; Volume 43, No. 8.	
	AJ	PASCHKE, E. et al.; Infantile type of sialic acid storage disease with sialuria; Clinical Genetics; 1986; pp. 417-424; Volume 29.	
	AK	RENLUND, MARTIN, M.D.; Clinical and laboratory diagnosis of Salla disease in infancy and childhood; The Journal of Pediatrics; 1984; pp. 232-236; Volume 104, No. 2	
	AL	RENLUND, MARTIN, et al.; Increased Urinary Excretion of Free N-Acetylneuraminic Acid in Thirteen Patients with Salla Disease; European Journal of Biochemistry; 1979; pp. 245-250; Volume 101	
	AM	RENLUND, MARTIN, M.D., et al.; Salla disease: A new lysosomal storage disorder with disturbed sialic acid metabolism; Neurology; January 1983; pp. 57-66; Volume 33	
	AN	RENLUND, MARTIN, et al.; Studies on the Defect Underlying the Lysosomal Storage of Sialic Acid in Salla Disease: Lysosomal Accumulation of Sialic Acid Formed From N-Acetyl-Mannosamine or Derived from Low Density Lipoprotein in Cultured Mutant Fibroblasts; Journal of Clinical Investigation; February 1986; pp. 568-574; Volume 77.	
	AO	RODRIGUEZ-SERNA, MERCEDES, Ph.D., et al. Angiokeratoma Corporis Diffusum Associated With β -Mannosidase Deficiency; Archives of Dermatology; October 1996; pp. 1219-1222; Volume 132.	
	AP	SANDOVAL, IGNACIO V.; et al.; Lysosomal Integral Membrane Glycoproteins Are Expressed at High Levels in the Inclusion Bodies of I-Cell Fibroblasts; Archives of Biochemistry and Biophysics; 1989; pp. 157-167; Volume 271, No. 1.	

Examiner
Signature

Peter J. Meikle

Date
Considered

5/20/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
DE 7069084 v1

RECEIVED

MAY 03 2002

RECEIVED
MAY 03 2002

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0633-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	09/180,657
Filing Date	November 12, 1998
First Named Inventor	Peter J. Meikle
Group Art Unit	1644
Examiner Name	Nolan, Patrick J.
Attorney Docket Number	021385-014500US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
PN	AA	5,501,957		Dennis, et al.	03-26-1996	

Examiner Signature	<i>Pat J. Nolan</i>	Date Considered	5/20/02
-----------------------	---------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DE 7069084 v1

Please type a plus sign (+) inside this box



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1

3

of

3

Complete if Known

Application Number	09/180,657
Filing Date	November 12, 1998
First Named Inventor	Peter J. Meikle
Group Art Unit	1644
Examiner Name	Nolan, Patrick J.
Attorney Docket Number	021385-014500US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PN	AQ	WAHEED, ABDUL, et al; Enhanced Breakdown of Arylsulfatase A in Multiple Sulfatase Deficiency; European Journal of Biochemistry; 1982; pp.317-321; volume 123.	
PN	AR	copy of International Search Report; Patent Cooperation Treaty Application No. PCT/AU 97/00304, dated August 15, 1997.	
PN	AS	copy of Supplementary Partial European Search Report; application number EP 97 92 0460, dated January 21, 2002.	

Examiner
Signature

Pat J. Nolan

Date
Considered

5/20/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
DE 7069084 v1

MAY 03 2002

RECEIVED